{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:02:05Z","timestamp":1791846125059,"version":"4.3.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40487-026-00417-y","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T13:43:30Z","timestamp":1771681410000},"page":"189-204","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neoadjuvant Therapy in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer: Recent Progress, Challenges, and Future Directions in the Era of TAR-200 and Enfortumab Vedotin Plus Pembrolizumab"],"prefix":"10.1007","volume":"14","author":[{"given":"Giuseppe","family":"Di Lorenzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Buonerba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"issue":"9","key":"417_CR1","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859\u201366. https:\/\/doi.org\/10.1056\/NEJMoa022148.","journal-title":"N Engl J Med"},{"key":"417_CR2","doi-asserted-by":"publisher","unstructured":"Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol. 2005;48(2):202\u20135. https:\/\/doi.org\/10.1016\/j.eururo.2005.04.006.","DOI":"10.1016\/j.eururo.2005.04.006"},{"issue":"5","key":"417_CR3","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","volume":"87","author":"AG van der Heijden","year":"2025","unstructured":"van der Heijden AG, Bruins HM, Carri\u00f3n A, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines. Eur Urol. 2025;87(5):582\u2013600. https:\/\/doi.org\/10.1016\/j.eururo.2025.02.019.","journal-title":"Eur Urol"},{"issue":"3","key":"417_CR4","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","volume":"33","author":"T Powles","year":"2022","unstructured":"Powles T, Bellmunt J, Comperat EM, et al. Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(3):244\u201358. https:\/\/doi.org\/10.1016\/j.annonc.2021.11.012.","journal-title":"Ann Oncol"},{"issue":"3","key":"417_CR5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S1470-2045(10)70275-8","volume":"12","author":"MD Galsky","year":"2011","unstructured":"Galsky MD, Hahn NM, Rosenberg J, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011;12(3):211\u20134. https:\/\/doi.org\/10.1016\/S1470-2045(10)70275-8.","journal-title":"Lancet Oncol"},{"issue":"3","key":"417_CR6","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-472822","volume":"45","author":"MJ Ribal","year":"2025","unstructured":"Ribal MJ, Rosenberg J, Ajami T, et al. Advancing perioperative treatment options for localized muscle-invasive bladder cancer: a step forward. Am Soc Clin Oncol Educ Book. 2025;45(3):e472822. https:\/\/doi.org\/10.1200\/EDBK-25-472822.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"19","key":"417_CR7","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","volume":"391","author":"T Powles","year":"2024","unstructured":"Powles T, Catto JWF, Galsky MD, et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N Engl J Med. 2024;391(19):1773\u201386. https:\/\/doi.org\/10.1056\/NEJMoa2408154.","journal-title":"N Engl J Med"},{"key":"417_CR8","unstructured":"US Food and Drug Administration. FDA approves durvalumab for muscle invasive bladder cancer. March 28, 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-durvalumab-muscle-invasive-bladder-cancer. Accessed 15 Dec 2025."},{"issue":"2","key":"417_CR9","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","volume":"82","author":"B Szabados","year":"2022","unstructured":"Szabados B, Kockx M, Assaf ZJ, et al. Final results of neoadjuvant atezolizumab in patients who are ineligible for cisplatin with muscle-invasive urothelial cancer of the bladder (ABACUS). Eur Urol. 2022;82(2):212\u201322. https:\/\/doi.org\/10.1016\/j.eururo.2022.04.013.","journal-title":"Eur Urol"},{"issue":"4","key":"417_CR10","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.eururo.2019.10.026","volume":"77","author":"A Necchi","year":"2020","unstructured":"Necchi A, Raggi D, Gallina A, et al. Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies. Eur Urol. 2020;77(4):439\u201346. https:\/\/doi.org\/10.1016\/j.eururo.2019.10.026.","journal-title":"Eur Urol"},{"issue":"12","key":"417_CR11","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","volume":"26","author":"N van Dijk","year":"2020","unstructured":"van Dijk N, Gil-Jimenez A, Silina K, et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med. 2020;26(12):1839\u201344. https:\/\/doi.org\/10.1038\/s41591-020-1085-z.","journal-title":"Nat Med"},{"issue":"10","key":"417_CR12","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, P\u00e9rez-Valderrama B, Gupta S, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390(10):875\u201388. https:\/\/doi.org\/10.1056\/NEJMoa2312117.","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"417_CR13","doi-asserted-by":"publisher","first-page":"S1763","DOI":"10.1016\/j.annonc.2025.09.124","volume":"36","author":"C Vulsteke","year":"2025","unstructured":"Vulsteke C, Kaimakliotis H, Danchaivijitr P, et al. Perioperative enfortumab vedotin plus pembrolizumab in participants with muscle-invasive bladder cancer who are cisplatin-ineligible: KEYNOTE-905\/EV-303. Ann Oncol. 2025;36(Suppl 2):S1763. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.124.","journal-title":"Ann Oncol"},{"key":"417_CR14","unstructured":"The ASCO Post. Perioperative immunotherapy regimen improves outcomes in cisplatin-ineligible muscle-invasive bladder cancer (KEYNOTE-905\/EV-303). November 10, 2025. https:\/\/ascopost.com\/issues\/november-10-2025\/perioperative-immunotherapy-regimen-improves-outcomes-in-cisplatin-ineligible-muscle-invasive-bladder-cancer\/. Accessed 15 Dec 2025."},{"key":"417_CR15","doi-asserted-by":"publisher","unstructured":"Necchi A, Guerrero-Ramos F, Crispen PL, et al. Gemcitabine intravesical system plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer: primary analysis and biomarker results of SunRISe-4. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO-25-02382.","DOI":"10.1200\/JCO-25-02382"},{"issue":"10","key":"417_CR16","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/S1470-2045(25)00358-4","volume":"26","author":"A Necchi","year":"2025","unstructured":"Necchi A, Guerrero-Ramos F, Crispen PL, et al. Neoadjuvant TAR-200 plus cetrelimab versus cetrelimab alone in cisplatin-ineligible or patients who declined cisplatin, muscle-invasive bladder cancer (SunRISe-4): an interim analysis of an open-label, randomised, phase\u00a02 trial. Lancet Oncol. 2025;26(10):1312\u201322. https:\/\/doi.org\/10.1016\/S1470-2045(25)00358-4.","journal-title":"Lancet Oncol"},{"issue":"33","key":"417_CR17","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1200\/JCO-25-01651","volume":"43","author":"S Daneshmand","year":"2025","unstructured":"Daneshmand S, van der Heijden MS, Jacob JM, et al. TAR-200 for Bacillus Calmette-Gu\u00e9rin-unresponsive high-risk non\u2013muscle-invasive bladder cancer: results from the phase\u00a0IIb SunRISe-1 study. J Clin Oncol. 2025;43(33):3578\u201388. https:\/\/doi.org\/10.1200\/JCO-25-01651.","journal-title":"J Clin Oncol"},{"key":"417_CR18","unstructured":"US Food and Drug Administration. FDA approves gemcitabine intravesical system for non-muscle-invasive bladder cancer. September 9, 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-gemcitabine-intravesical-system-non-muscle-invasive-bladder-cancer. Accessed 15 Dec 2025."},{"issue":"4","key":"417_CR19","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","volume":"22","author":"J Bellmunt","year":"2021","unstructured":"Bellmunt J, Hussain M, Gschwend JEG, et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase\u00a03 trial. Lancet Oncol. 2021;22(4):525\u201337. https:\/\/doi.org\/10.1016\/S1470-2045(21)00004-8.","journal-title":"Lancet Oncol"},{"issue":"2","key":"417_CR20","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","volume":"85","author":"T Powles","year":"2024","unstructured":"Powles T, Assaf ZJ, Degaonkar V, et al. Updated overall survival analysis of IMvigor010 by circulating tumor DNA status in muscle-invasive urothelial carcinoma. Eur Urol. 2024;85(2):114\u201322. https:\/\/doi.org\/10.1016\/j.eururo.2023.06.007.","journal-title":"Eur Urol"},{"issue":"24","key":"417_CR21","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","volume":"393","author":"T Powles","year":"2025","unstructured":"Powles T, Kann AG, Castellano D, et al. ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer. N Engl J Med. 2025;393(24):2395\u2013408. https:\/\/doi.org\/10.1056\/NEJMoa2511885.","journal-title":"N Engl J Med"},{"issue":"1","key":"417_CR22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.euo.2023.05.012","volume":"7","author":"E Crupi","year":"2024","unstructured":"Crupi E, de Padua TC, Marandino L, et al. Circulating tumor DNA as a predictive and prognostic biomarker in the perioperative treatment of muscle-invasive bladder cancer: a systematic review. Eur Urol Oncol. 2024;7(1):44\u201352. https:\/\/doi.org\/10.1016\/j.euo.2023.05.012.","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"417_CR23","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.euf.2025.06.009","volume":"11","author":"J Lee","year":"2025","unstructured":"Lee J, Chen F, Lopez-Beltran A, et al. Urinary tumor DNA-based liquid biopsy in bladder cancer management: a systematic review. Eur Urol Focus. 2025;11(6):978\u201390. https:\/\/doi.org\/10.1016\/j.euf.2025.06.009.","journal-title":"Eur Urol Focus"},{"issue":"10139","key":"417_CR24","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/S0140-6736(18)31078-X","volume":"391","author":"MJM van der Valk","year":"2018","unstructured":"van der Valk MJM, Hilling DE, Bastiaannet E, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet. 2018;391(10139):2537\u201345. https:\/\/doi.org\/10.1016\/S0140-6736(18)31078-X.","journal-title":"Lancet"},{"issue":"22","key":"417_CR25","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 2021;384(22):2102\u201314. https:\/\/doi.org\/10.1056\/NEJMoa2034442.","journal-title":"N Engl J Med"},{"issue":"1","key":"417_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa2401726","volume":"392","author":"AB Apolo","year":"2025","unstructured":"Apolo AB, Ballman KV, Sonpavde G, et al. Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma. N Engl J Med. 2025;392(1):45\u201355. https:\/\/doi.org\/10.1056\/NEJMoa2401726.","journal-title":"N Engl J Med"},{"issue":"3","key":"417_CR27","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540-56.e25. https:\/\/doi.org\/10.1016\/j.cell.2017.09.007.","journal-title":"Cell"},{"key":"417_CR28","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1016\/j.cell.2024.05.029","volume":"187","author":"L Derosa","year":"2024","unstructured":"Derosa L, Iebba V, Silva CAC, et al. Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome. Cell. 2024;187:3373-3389.e16. https:\/\/doi.org\/10.1016\/j.cell.2024.05.029.","journal-title":"Cell"},{"issue":"5","key":"417_CR29","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.eururo.2023.12.014","volume":"85","author":"F Pederzoli","year":"2024","unstructured":"Pederzoli F, Riba M, Venegoni C, et al. Stool microbiome signature associated with response to neoadjuvant pembrolizumab in patients with muscle-invasive bladder cancer. Eur Urol. 2024;85(5):417\u201321. https:\/\/doi.org\/10.1016\/j.eururo.2023.12.014.","journal-title":"Eur Urol"},{"issue":"3","key":"417_CR30","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.eururo.2021.05.018","volume":"80","author":"F Pederzoli","year":"2021","unstructured":"Pederzoli F, Bandini M, Raggi D, et al. Is there a detrimental effect of antibiotic therapy in patients with muscle-invasive bladder cancer treated with neoadjuvant pembrolizumab? Eur Urol. 2021;80(3):319\u201322. https:\/\/doi.org\/10.1016\/j.eururo.2021.05.018.","journal-title":"Eur Urol"},{"issue":"4","key":"417_CR31","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.eururo.2020.06.061","volume":"78","author":"AM Hopkins","year":"2020","unstructured":"Hopkins AM, Kichenadasse G, Karapetis CS, et al. Concomitant antibiotic use and survival in urothelial carcinoma treated with atezolizumab. Eur Urol. 2020;78(4):540\u20133. https:\/\/doi.org\/10.1016\/j.eururo.2020.06.061.","journal-title":"Eur Urol"},{"key":"417_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-025-01075-x","author":"D Raggi","year":"2025","unstructured":"Raggi D, Martini A, Cattrini C, et al. HER2 and urothelial carcinoma: current evidence and future directions. Nat Rev Urol. 2025. https:\/\/doi.org\/10.1038\/s41585-025-01075-x.","journal-title":"Nat Rev Urol"},{"key":"417_CR33","doi-asserted-by":"publisher","unstructured":"Crupi E, Costa de Padua T, Marandino L, et al. Nectin-4 positivity in genitourinary malignancies: a systematic review. JCO Precis Oncol. 2024;8:e2400470. https:\/\/doi.org\/10.1200\/PO-24-00470.","DOI":"10.1200\/PO-24-00470"},{"issue":"1","key":"417_CR34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.eururo.2025.03.017","volume":"89","author":"S Gupta","year":"2026","unstructured":"Gupta S, Hensley PJ, Li R, et al. Bladder preservation strategies in muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. Eur Urol. 2026;89(1):18\u201328. https:\/\/doi.org\/10.1016\/j.eururo.2025.03.017.","journal-title":"Eur Urol"},{"issue":"16","key":"417_CR35","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","volume":"366","author":"ND James","year":"2012","unstructured":"James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366(16):1477\u201388. https:\/\/doi.org\/10.1056\/NEJMoa1106106.","journal-title":"N Engl J Med"},{"issue":"6","key":"417_CR36","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","volume":"71","author":"NJ Giacalone","year":"2017","unstructured":"Giacalone NJ, Shipley WU, Clayman RH, et al. Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience. Eur Urol. 2017;71(6):952\u201360. https:\/\/doi.org\/10.1016\/j.eururo.2016.12.020.","journal-title":"Eur Urol"},{"issue":"34","key":"417_CR37","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","volume":"32","author":"RH Mak","year":"2014","unstructured":"Mak RH, Hunt D, Shipley WU, et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols. J Clin Oncol. 2014;32(34):3801\u20139. https:\/\/doi.org\/10.1200\/JCO.2014.57.5548.","journal-title":"J Clin Oncol"},{"issue":"2","key":"417_CR38","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.euf.2022.12.012","volume":"9","author":"G Tissot","year":"2023","unstructured":"Tissot G, Xylinas E. Efficacy and safety of pembrolizumab in combination with chemoradiotherapy versus chemoradiotherapy alone in muscle-invasive bladder cancer: the MK-3475-992\/KEYNOTE-992 trial. Eur Urol Focus. 2023;9(2):227\u20138. https:\/\/doi.org\/10.1016\/j.euf.2022.12.012.","journal-title":"Eur Urol Focus"},{"key":"417_CR39","doi-asserted-by":"publisher","unstructured":"Gupta S, Fujii Y, van der Heijden MS, et al. Phase\u00a03 KEYNOTE-992 study of pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with muscle-invasive bladder cancer (MIBC). J Clin Oncol. 2024;42(4_suppl):TPS720. https:\/\/doi.org\/10.1200\/JCO.2024.42.4_suppl.TPS720. Presented at: 2024 ASCO Genitourinary Cancers Symposium; January 25\u201327, 2024; San Francisco, CA.","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS720"},{"issue":"6_suppl","key":"417_CR40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS586","volume":"38","author":"P Singh","year":"2020","unstructured":"Singh P, Tangen C, Efstathiou JA, et al. INTACT: phase\u00a0III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer: SWOG\/NRG S1806. J Clin Oncol. 2020;38(6_suppl):TPS586. https:\/\/doi.org\/10.1200\/JCO.2020.38.6_suppl.TPS586.","journal-title":"J Clin Oncol"},{"issue":"6","key":"417_CR41","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.prro.2025.05.004","volume":"15","author":"V Achard","year":"2025","unstructured":"Achard V, Abdel-Aty H, Duque-Santana V, et al. Combining radiation therapy with immune checkpoint inhibitors for the management of muscle-invasive bladder cancer: a comprehensive systematic review from the Y-ECI ROSC EORTC group. Pract Radiat Oncol. 2025;15(6):610\u201324. https:\/\/doi.org\/10.1016\/j.prro.2025.05.004.","journal-title":"Pract Radiat Oncol"},{"key":"417_CR42","unstructured":"Johnson & Johnson. Johnson & Johnson Statement on the SunRISe-2 Study. News release. October 7, 2024. https:\/\/www.jnj.com\/media-center\/press-releases\/johnson-johnson-statement-on-the-sunrise-2-study. Accessed 18 Jan 2026."},{"key":"417_CR43","unstructured":"ClinicalTrials.gov. Perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in muscle-invasive bladder cancer (KEYNOTE-B15\/EV-304). NCT04700124. https:\/\/clinicaltrials.gov\/study\/NCT04700124. Accessed 15 Dec 2025."},{"key":"417_CR44","unstructured":"Astellas Pharma Inc.; Pfizer Inc. PADCEV\u2122 plus Keytruda\u00ae significantly improves survival for patients with muscle-invasive bladder cancer regardless of cisplatin eligibility (press release). December 17, 2025. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/padcevtm-plus-keytrudar-significantly-improves-survival. Accessed 18 Jan 2026."},{"key":"417_CR45","unstructured":"Merck & Co., Inc. KEYTRUDA\u00ae (pembrolizumab) plus Padcev\u00ae (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response rates for patients who are eligible for cisplatin with MIBC when given before and after surgery (press release). December 17, 2025. https:\/\/www.merck.com\/news\/keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-significantly-improved-event-free-survival-overall-survival-and-pathologic-complete-response-rates-for-cisplatin-eligible-pa\/. Accessed 18 Jan 2026."},{"key":"417_CR46","unstructured":"ClinicalTrials.gov. Pembrolizumab plus chemoradiotherapy versus chemoradiotherapy alone in muscle-invasive bladder cancer (KEYNOTE-992). NCT04241185. https:\/\/clinicaltrials.gov\/study\/NCT04241185. Accessed 15 Dec 2025."},{"key":"417_CR47","unstructured":"ClinicalTrials.gov. Concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer (S1806). NCT03775265. https:\/\/clinicaltrials.gov\/study\/NCT03775265. Accessed 15 Dec 2025."},{"key":"417_CR48","unstructured":"ClinicalTrials.gov. Durvalumab with neoadjuvant chemotherapy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA). NCT03732677. https:\/\/clinicaltrials.gov\/study\/NCT03732677. Accessed 15 Dec 2025."},{"key":"417_CR49","unstructured":"ClinicalTrials.gov. Adjuvant atezolizumab versus observation in muscle invasive urothelial carcinoma (IMvigor010). NCT02450331. https:\/\/clinicaltrials.gov\/study\/NCT02450331. Accessed 15 Dec 2025."},{"issue":"11","key":"417_CR50","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1613683.","journal-title":"N Engl J Med"},{"issue":"13","key":"417_CR51","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Dur\u00e1n I, van der Heijden MS, et al. Avelumab maintenance therapy for advanced urothelial carcinoma. N Engl J Med. 2020;383(13):1218\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2002788.","journal-title":"N Engl J Med"},{"issue":"12","key":"417_CR52","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2035807.","journal-title":"N Engl J Med"},{"issue":"10","key":"417_CR53","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","volume":"76","author":"PM Challita-Eid","year":"2016","unstructured":"Challita-Eid PM, Satpayev D, Yang P, et al. Enfortumab vedotin antibody-drug conjugate targeting Nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. 2016;76(10):3003\u201313. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1313.","journal-title":"Cancer Res"},{"issue":"6","key":"417_CR54","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1056\/NEJMc2415733","volume":"392","author":"S Koga","year":"2025","unstructured":"Koga S, Mei L. Perioperative durvalumab in bladder cancer. N Engl J Med. 2025;392(6):618\u20139. https:\/\/doi.org\/10.1056\/NEJMc2415733.","journal-title":"N Engl J Med"},{"issue":"6","key":"417_CR55","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/NEJMc2415733","volume":"392","author":"T Powles","year":"2025","unstructured":"Powles T, Galsky MD, van der Heijden MS. Perioperative durvalumab in bladder cancer. Reply. N Engl J Med. 2025;392(6):619. https:\/\/doi.org\/10.1056\/NEJMc2415733.","journal-title":"N Engl J Med"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00417-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-026-00417-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00417-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T13:44:34Z","timestamp":1773668674000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-026-00417-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["417"],"URL":"https:\/\/doi.org\/10.1007\/s40487-026-00417-y","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Giuseppe Di Lorenzo is an Editorial Board member of\n                      Oncology and Therapy\n                      . Giuseppe Di Lorenzo was not involved in the selection of peer reviewers for this manuscript nor in any of the subsequent editorial decisions. Carlo Buonerba reports consulting\/speaker fees from Ipsen and Bayer and institutional funding by Astrazeneca. Massimo Di Maio reports honoraria from AstraZeneca, Boehringer Ingelheim, Janssen, Merck Sharp & Dohme (MSD), Novartis, Pfizer, Roche, GlaxoSmithKline, Viatris, Resilience, Daiichi Sankyo for consultancy or participation to advisory boards and institutional funding for work in clinical trials\/contracted research from Beigene, Exelixis, MSD, Pfizer and Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}